FINV
FINAL DECISION TRANSACTION PROCESSED BY IB
12/28/2024
Back to search
Official data from USPTO
DC PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
26
Latest update
04/03/2026
Classification
Registered
Trademark type
Combined
Nice classes
5
Filing date
02/10/2023
Registration date
06/25/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/25/2024
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
CN
Examiner
MORRIS, KRISTINA KLOIBER
Law office
M70
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of four Chinese characters and stylized letters "DC PHARMA" to the right and a design of two semicircles of irregular shapes to the left.
Holders and representatives
Holders
YANTAI DONGCHENG BIOCHEMICALS CO., LTD.
Representatives
Alexander Butterman Dunlap Bennett & Ludwig PLLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Diagnostic radiopharmaceutical preparations; vitamin tablets; medicines for human purposesmedicines for the treatment of diabetesobesitycanceroncological diseasescardiovascular and cerebrovascular diseasescoldscoughinfluenzarespiratory diseases and asthmagastrointestinal diseasesgenitourinary diseasesneurological diseasesallergiesheadachesinsomniabacteria-based diseasesocular disorders or diseases; biochemical medicines for the treatment of cancer; liquid herbal supplements; medicinal drinks; capsules sold empty for pharmaceuticals; pharmaceutical preparationsantivirals; radioactive substances for medical purposes; pharmaceutical preparations for treating chemical imbalances; mixed biological preparations for the prevention and treatment of infectious diseases; isotopes for medical purposes; diagnostic reagents for medicinal use; diagnostic preparations for medical purposes; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; injectable pharmaceuticals for treatment of anaphylactic reactions; medicines made of Chinese traditional medicinal herbs; dietary supplements
Publications
History of USPTO decisions and trademark events.
26 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
12/11/2024
FIMP
FINAL DISPOSITION PROCESSED
12/10/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
09/25/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/25/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
06/25/2024
GPNX
NOTIFICATION PROCESSED BY IB
04/16/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/09/2024
PUBO
PUBLISHED FOR OPPOSITION
04/09/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/27/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
03/27/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/20/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/01/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/21/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/21/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/21/2024
RFNT
REFUSAL PROCESSED BY IB
12/19/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
11/28/2023
RFRR
REFUSAL PROCESSED BY MPU
11/28/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/23/2023
CNRT
NON-FINAL ACTION WRITTEN
11/22/2023
DOCK
ASSIGNED TO EXAMINER
11/09/2023
MAFR
APPLICATION FILING RECEIPT MAILED
04/06/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/02/2023
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
03/30/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/30/2023
Continuous trademark protection
Get notified about every new filing that threatens DC PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.